International scientific research on venture capital: a bibliometric and mapping analysis from the period 1978–2020

The aim of this study is to explore the relevance of scientific production on venture capital using bibliometric and mapping tools.We performed a search in Scopus, involving any document published between 1978 and 2020. We used bibliometric indicators to explore documents production, dispersion, distribution, time of duplication, and annual growth, as Price’s law of scientific literature growth, Lotka’s law, the transient index, and the Bradford model. We also calculated the participation index of the different countries and institutions. Finally, we explored the co-occurrence and thematic networks for the most frequently used terms in venture capital research through bibliometric mapping.A total of 1,230 original articles were collected from the timeframe 1978–2020. The model confirms that Price’s law is not fulfilled. Scientific production was better adjusted to linear growth (r = 0.9290) than exponential (r = 0.9161). Literature on venture capital research has increased its growth in the last 43 years at a rate of 7.9% per year, with a production that doubles its size every 9.1 years. The transience index was 79.91%, which indicates that most of the scientific production is due to a lot of authors with a small number of publications on the research topic. Bradford´s law shows that the scientific production in this area is widely distributed in multiple journals, and Lotka’s law indicates that the author’s distribution is heavily concentrated on small producers. The United States of America (USA) and the University of Pennsylvania present the highest production, contributing 31.22% and 1.63% of the total production of research on venture capital.The venture capital task has undergone a linear growth, with a very high rate of transience, which indicates the presence of numerous authors who sporadically publish on this topic. No evidence of a saturation point was observed in the scientific production analyzed, which makes it possible to conclude that the research in venture capital will continue to be in demand by the scientific community.The aim of this study is to explore the relevance of scientific production on venture capital using bibliometric and mapping tools.We performed a search in Scopus, involving any document published between 1978 and 2020. We used bibliometric indicators to explore documents production, dispersion, distribution, time of duplication, and annual growth, as Price’s law of scientific literature growth, Lotka’s law, the transient index, and the Bradford model. We also calculated the participation index of the different countries and institutions. Finally, we explored the co-occurrence and thematic networks for the most frequently used terms in venture capital research through bibliometric mapping.A total of 1,230 original articles were collected from the timeframe 1978–2020. The model confirms that Price’s law is not fulfilled. Scientific production was better adjusted to linear growth (r = 0.9290) than exponential (r = 0.9161). Literature on venture capital research has increased its growth in the last 43 years at a rate of 7.9% per year, with a production that doubles its size every 9.1 years. The transience index was 79.91%, which indicates that most of the scientific production is due to a lot of authors with a small number of publications on the research topic. Bradford´s law shows that the scientific production in this area is widely distributed in multiple journals, and Lotka’s law indicates that the author’s distribution is heavily concentrated on small producers. The United States of America (USA) and the University of Pennsylvania present the highest production, contributing 31.22% and 1.63% of the total production of research on venture capital.The venture capital task has undergone a linear growth, with a very high rate of transience, which indicates the presence of numerous authors who sporadically publish on this topic. No evidence of a saturation point was observed in the scientific production analyzed, which makes it possible to conclude that the research in venture capital will continue to be in demand by the scientific community

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

BACKGROUN

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin- kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. We sought to evaluate the efficacy of bococizumab in patients at high cardiovascular risk. METHODS In two parallel, multinational trials with different entry criteria for LDL cholesterol levels, we randomly assigned the 27,438 patients in the combined trials to receive bococizumab (at a dose of 150 mg) subcutaneously every 2 weeks or placebo. The primary end point was nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina requiring urgent revascularization, or cardiovascular death; 93% of the patients were receiving statin therapy at baseline. The trials were stopped early after the sponsor elected to discontinue the development of bococizumab owing in part to the development of high rates of antidrug antibodies, as seen in data from other studies in the program. The median follow-up was 10 months. RESULTS At 14 weeks, patients in the combined trials had a mean change from baseline in LDL cholesterol levels of -56.0% in the bococizumab group and +2.9% in the placebo group, for a between-group difference of -59.0 percentage points (P<0.001) and a median reduction from baseline of 64.2% (P<0.001). In the lower-risk, shorter-duration trial (in which the patients had a baseline LDL cholesterol level of ≥70 mg per deciliter [1.8 mmol per liter] and the median follow-up was 7 months), major cardiovascular events occurred in 173 patients each in the bococizumab group and the placebo group (hazard ratio, 0.99; 95% confidence interval [CI], 0.80 to 1.22; P = 0.94). In the higher-risk, longer-duration trial (in which the patients had a baseline LDL cholesterol level of ≥100 mg per deciliter [2.6 mmol per liter] and the median follow-up was 12 months), major cardiovascular events occurred in 179 and 224 patients, respectively (hazard ratio, 0.79; 95% CI, 0.65 to 0.97; P = 0.02). The hazard ratio for the primary end point in the combined trials was 0.88 (95% CI, 0.76 to 1.02; P = 0.08). Injection-site reactions were more common in the bococizumab group than in the placebo group (10.4% vs. 1.3%, P<0.001). CONCLUSIONS In two randomized trials comparing the PCSK9 inhibitor bococizumab with placebo, bococizumab had no benefit with respect to major adverse cardiovascular events in the trial involving lower-risk patients but did have a significant benefit in the trial involving higher-risk patients